The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review

Bibliographic Details
Main Authors:	M Connock, A Burls, E Frew, A Fry-Smith, A Juarez-Garcia, C McCabe, A Wailoo, K Abrams, N Cooper, A Sutton, A O'Hagan, D Moore
Format:	Article
Language:	English
Published:	NIHR Journals Library 2006-07-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta10240

Similar Items

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
by: Connock, M, et al.
Published: (2006)

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review
by: Connock, M, et al.
Published: (2006)

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
by: Connock, M, et al.
Published: (2006)

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1
by: M Connock, et al.
Published: (2006-06-01)

Enzyme replacement in Gaucher disease.
by: Ernest Beutler
Published: (2004-11-01)

Enzyme replacement therapy in adult patients with type I Gaucher disease
by: R V Ponomarev, et al.
Published: (2019-07-01)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
by: Derralynn A. Hughes, et al.
Published: (2022-08-01)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
by: Cummins, C, et al.
Published: (2002)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
by: Cummins, C, et al.
Published: (2002)

MiRNA Expression in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
by: Łukasz Pawliński, et al.
Published: (2020-12-01)

Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature
by: Gökhan Kabaçam, et al.
Published: (2010-09-01)

Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature
by: Gökhan Kabaçam, et al.
Published: (2010-10-01)

Pulmonary Involvement Responsive to Enzyme Replacement Therapy in an Elderly Patient with Gaucher Disease
by: Dylan Vellas, et al.
Published: (2021-10-01)

Down-regulation of Regulatory T-cells in Children With Gaucher Disease Under Enzyme Replacement Therapy
by: Asmaa M. Zahran MD, et al.
Published: (2019-11-01)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
by: Renuka P. Limgala, et al.
Published: (2020-03-01)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
by: Amal El Beshlawy, et al.
Published: (2019-09-01)

Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: Systematic review and meta-analysis
by: Moore, D, et al.
Published: (2009)

Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis.
by: Moore, D, et al.
Published: (2009)

Symmetric, bilateral upper and lower extremity lucent lesions in a patient with Gaucher's disease on enzyme replacement therapy
by: Andrew S. Kuhn, MD, et al.
Published: (2020-11-01)

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
by: Wang, D, et al.
Published: (2008)

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
by: Wang, D, et al.
Published: (2008)

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis
by: D Wang, et al.
Published: (2008-02-01)

Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment
by: Paola Iaccarino Idelson, et al.
Published: (2022-08-01)

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review
by: M Connock, et al.
Published: (2006-03-01)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
by: Majdolen Istaiti, et al.
Published: (2022-10-01)

a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy.
by: Marina Moraitou, et al.
Published: (2023-01-01)

a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy
by: Marina Moraitou, et al.
Published: (2023-01-01)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
by: Ni-Chung Lee, et al.
Published: (2022-06-01)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.
by: Renuka Pudi Limgala, et al.
Published: (2016-01-01)

Nicotine replacement therapy. Authors respond to criticism that treatment is ineffective.
by: Aveyard, P, et al.
Published: (2009)

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B
by: D Turner, et al.
Published: (2003-11-01)

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
by: Connock, M, et al.
Published: (2007)

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
by: Connock, M, et al.
Published: (2007)

Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation
by: Connock, M, et al.
Published: (2007)

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation
by: M Connock, et al.
Published: (2007-03-01)

Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
by: Dominick Amato, et al.
Published: (2018-01-01)

Gaucher Disease and Gaucher Cells
by: Sevgi Gözdaşoğlu
Published: (2015-05-01)

Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
by: Trapero, A, et al.
Published: (2011)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
by: Yoo-Mi Kim, et al.
Published: (2017-05-01)

The probability of cost-effectiveness
by: Stevens John W, et al.
Published: (2002-03-01)